We recently compiled a list of the 10 Best Small-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

A downtrend has been apparent in Arvinas, Inc. (ARVN) lately. While the stock has lost 14.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session.

Summary. I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials.

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with Pfizer (PFE). Read more here.